Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.
IPO Year: 2015
Exchange: NASDAQ
Website: jaguar.health
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/7/2021 | $5.00 | Overweight | Cantor Fitzgerald |
FDA-approved Gelclair® is company's third commercialized prescription productSusan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar family company Napo Pharmaceuticals."Sue is a dynamic and proven commercial leader with 30 years of experience in the biopharmaceuticals industry - including 15 years of recent experience in the oncology market - building high-performing teams and exceeding sales targets. We ar
Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine Miller Collis to the role of Senior Vice President of Growth Strategy."Cathy Collis was instrumental in bringing about the Gelclair in-license agreement. She is a results-oriented commercial leader with more than 25 years of experience in the biopharmaceutical industry, and
Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S.Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium priceSAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International. A European pharmaceutical industry leader and entrepreneur with more than 35 years' experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases, Dr
Greg Divis departs from Jaguar's Board of Directors; Experienced business development executive Rachel Zolot Schwartz chairs new committeeSAN FRANCISCO, CA / ACCESSWIRE / July 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that it has appointed Anula Jayasuriya, M.D., Ph.D., M.B.A., to the company's Board of Directors, effective July 1, 2022. Dr. Jayasuriya is a highly experienced healthcare private equity executive and venture capitalist with broad clinical, industry, entrepreneurial, and investment experience. Jaguar today also announced that it has established a Business Development Advisory Committee to identify and assess opportunities for potential alliances, merg
Dr. Chaturvedi continues to serve as Chair of company's Scientific Advisory BoardDr. Chaturvedi continues to provide leadership to the development of two crofelemer pipeline indications, with anticipated key milestones in the next 12-15 months.SAN FRANCISCO, CA / ACCESSWIRE / April 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Pravin Chaturvedi, PhD, a pharmaceutical veteran and leading clinical development expert, has been appointed Chief Scientific Officer (CSO) and Chair of the Scientific Advisory Board (SAB) of Jaguar. Prior to this appointment, Dr. Chaturvedi served as Chair of the company's SAB and Acting CSO of Jaguar and Napo Pharmaceuticals (Napo), Jaguar
Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases - beginning with short bowel syndrome (SBS)For SBS, Napo Therapeutics has been granted Orphan-Drug Designation for crofelemer by the European Medicines Agency, and Jaguar Health has been granted Orphan-Drug Designation for crofelemer by the FDASAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / January 24, 2022 / Jaguar Health (NASDAQ:JAGX) and Napo Therapeutics S.p.A., an Italian corporation established by Jaguar Health in Italy, today announced the appointment of Martire Particco, MD, a physician with 30+ years of experience in Europe's pharmaceutical industry and in c
REMINDER: Jaguar to host investor webcast Wednesday, November 17th at 8:30 a.m. Eastern regarding third quarter 2021 financials & business updates; Click here to register for webcastSAN FRANCISCO, CA / ACCESSWIRE / November 16, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the appointment of Massimo Mineo, a veteran of Europe's pharmaceutical industry for 20+ years, as Napo EU's general manager."We are thrilled to have Massimo on board for this key leadership role at Napo EU in Milan," stated Lisa Conte, Jaguar's president and CEO and Napo EU board member. "Massimo is an established leader and senior manager in the European pharmaceutical arena, and he possesses a great deal of ex
SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the appointment by Napo EU S.p.A., the company's Italian subsidiary, of Annabella Amatulli as chief regulatory officer. A recognized expert in global regulatory affairs, Ms. Amatulli will be responsible for both high-level strategic planning and hands-on support for Napo EU's development programs and licensed products from a regulatory perspective and serve as the primary liaison between Napo EU and European health authorities."We consider ourselves very fortunate to have identified Annabella for this very important role at Napo EU, and even more fortunate that she has joined as the first me
Appointments represent Jaguar's focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization of crofelemer prescription product for chemotherapy-induced diarrhea in dogsCompany to host investor webcast Monday, September 20th at 8:30 a.m. Eastern; Click here to register for webcastSAN FRANCISCO, CA / ACCESSWIRE / September 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the appointment of Karen J. Brunke, Ph.D., a microbiologist and pharmaceutical industry veteran, to the role of Executive Vice President of Corporate and Business Development. Jagua
Proposals 1, 2, 4, 5 & 6 approvedSAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's May 13, 2021 Annual Meeting of Stockholders, which was adjourned until September 3, 2021.Six items of business were addressed at the meeting today:Proposal 1: To elect one Class III director.Proposal 2: To ratify the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2021.Proposal 3: To approve an amendment to the Company's Third Amended and Restated Certificate of Incorporation, as amended (the "COI"), t
Mytesi® net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019 SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2020. 2020 Company Financial Results: Mytesi® Net Product Revenue: 2020 Mytesi net sales were approximately $9.3 million, and Mytesi gross (non-GAAP) sales were approximately $20.4 million, an increase of 64% and 148%, respectively, year over year. In 2020, the Company's animal product research and development efforts were intentionally minimal, and Jaguar's animal-related sales were also minimal.
4 - Jaguar Health, Inc. (0001585608) (Issuer)
4 - Jaguar Health, Inc. (0001585608) (Issuer)
4 - Jaguar Health, Inc. (0001585608) (Issuer)
4 - Jaguar Health, Inc. (0001585608) (Issuer)
4 - Jaguar Health, Inc. (0001585608) (Issuer)
4 - Jaguar Health, Inc. (0001585608) (Issuer)
4 - Jaguar Health, Inc. (0001585608) (Issuer)
4 - Jaguar Health, Inc. (0001585608) (Issuer)
4 - Jaguar Health, Inc. (0001585608) (Issuer)
4 - Jaguar Health, Inc. (0001585608) (Issuer)
S-8 - Jaguar Health, Inc. (0001585608) (Filer)
8-K - Jaguar Health, Inc. (0001585608) (Filer)
10-Q - Jaguar Health, Inc. (0001585608) (Filer)
8-K - Jaguar Health, Inc. (0001585608) (Filer)
8-K - Jaguar Health, Inc. (0001585608) (Filer)
424B5 - Jaguar Health, Inc. (0001585608) (Filer)
8-K - Jaguar Health, Inc. (0001585608) (Filer)
8-K - Jaguar Health, Inc. (0001585608) (Filer)
8-K - Jaguar Health, Inc. (0001585608) (Filer)
8-K - Jaguar Health, Inc. (0001585608) (Filer)
Cantor Fitzgerald initiated coverage of Jaguar Health with a rating of Overweight and set a new price target of $5.00
SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)
SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)
SC 13G - Jaguar Health, Inc. (0001585608) (Subject)
SC 13G - Jaguar Health, Inc. (0001585608) (Subject)
SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)
SC 13G - Jaguar Health, Inc. (0001585608) (Subject)
SC 13G - Jaguar Health, Inc. (0001585608) (Subject)
SC 13G - Jaguar Health, Inc. (0001585608) (Subject)
SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)
SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)
FDA-approved Gelclair® is company's third commercialized prescription productSusan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar family company Napo Pharmaceuticals."Sue is a dynamic and proven commercial leader with 30 years of experience in the biopharmaceuticals industry - including 15 years of recent experience in the oncology market - building high-performing teams and exceeding sales targets. We ar
SAN FRANCISCO, CA / ACCESSWIRE / September 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will be presenting virtually, and meeting virtually with investors, at the H.C. Wainwright 26th Annual Global Investment Conference, which takes place September 9-11, 2024.Participation Instructions for Jaguar Health's Presentation at the H.C. Wainwright 26th Annual Global Investment ConferenceWhen: On-demand virtual presentation available starting at 7:00 AM Eastern on Monday, September 9, 2024Webcast Link: Click here to access the presentationWhere: The conference is taking place virtually and in-person at Lotte New York Palace, 4
Company's Canalevia®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / September 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") is proud to be celebrating National Service Dog Month, a time devoted to raising awareness and showing appreciation for the extraordinary work service dogs do every day for the people in their care."September is National Service Dog Month. Service dogs are incredible working animals who enable people to live more independently and enjoy a better quality of life. In some ca
Click here to view interview videoParamount near-term activities include planned October 2024 commercial launch of FDA-approved oral mucositis prescription product Gelclair® and results from independent, investigator-initiated trials of crofelemer for rare diseases SAN FRANCISCO, CA / ACCESSWIRE / September 4, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a new Innovators with Jane King video interview of Lisa Conte, Jaguar's founder, president, and CEO, is available and can be viewed by clicking here."Our paramount near-term activities are our planned October 2024 commercial launch of the FDA-approved oral mucositis prescription product Gelclair in the U.S. and pr
New patent issued for core rare disease target indication for crofelemerNapo has approximately 230 patents issued and pendingJaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the country of Jordan's Industrial Property Protection Directorate has issued a new patent to Jaguar family company Nap
Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Eduardo Zimmer, Ph.D., a key collaborator with Magdalena Biosciences ("Magdalena"), the joint venture formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF)(CBOE CA:FH)(FSE:7QS) to develop novel, natural prescription psychoactive medicines derived from plants for mental health indications, is the 2024 recipient of the prestigious Blas Frangione Early Career Achievement Award. This awa
New patent issued for core rare disease target indication for crofelemerNapo has approximately 230 patents issued and pendingJaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Hong Kong's Intellectual Property Department has issued a new patent to Jaguar family company Napo Pharmaceuticals for
The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 millionCompany to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in support of FDA discussion; Jaguar to explore possible approval pathway for crofelemer in breast and lung cancer based on phase 3 resultsJaguar planning to begin commercial launch in October 2024 for Gelclair®, the company's third prescription productImport permit for crofelemer
In 2022 breast cancer was the most common cancer in women in 157 countries out of 185, and lung cancer is the most common cancer worldwide.1 Click here to register for webcast.Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi of crofelemer in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure SAN FRANCISCO, CA / ACCESSWIRE / August 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today issued a letter to shareholders from the company's founder, president, and chief executive officer, Lisa Conte.Dear Fellow Shareholders
It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of two independent investigator-initiated studies of crofelemer, Napo's novel, plant-based oral prescription drug, showed a benefit in patients with chronic refractory diarrhea and have been accepted for poster presentations at the American College of Gastroenterology Annual Scientific Meeting, which takes place October 25-30, 2024 at the Pennsylvania Convention Center in Philadelphia."We are very excited that crofelemer continues to demonstrate clinical
U.S. stocks traded slightly higher toward the end of trading, with the Dow Jones gaining by more than 50 points on Tuesday. The Dow traded up 0.17% to 40,483.92 while the NASDAQ rose 0.20% to 18,043.64. The S&P 500 also rose, gaining, 0.14% to 5,572.07. Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report Leading and Lagging SectorsConsumer discretionary shares jumped by 0.5% on Tuesday. In trading on Tuesday, energy shares fell by 1.4%. Top Headline Coca-Cola Company (NYSE:KO) reported better-than-expected second-quarter results and raised its guidance. The company reported second-quarter FY24 sales growth of 3% year-on-year to $12.4
Shares of Comcast Corporation (NASDAQ:CMCSA) fell sharply during Tuesday's session after the company reported worse-than-expected second-quarter sales results. Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from Benzinga Pro. Comcast shares declined 6.1% to $37.12 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Azitra, Inc. (NYSE:AZTR) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office grant
Jaguar Health, Inc. (NASDAQ:JAGX) shares are falling Tuesday after the company announced its phase 3 OnTarget trial results for crofelemer did not meet its primary endpoint. The Details: Jaguar Health said the initial results from its OnTarget study for crofelemer show the multicenter, double-blind, placebo-controlled pivotal clinical trial did not meet its primary endpoint for the prespecified analysis of all tumor types in the trial. Crofelemer is an FDA-approved prescription drug for the symptomatic relief of diarrhea in adult HIV/AIDS patients receiving antiretroviral therapy. "We believe the OnTarget trial, designed boldly to address a broad array of cancer patients undergoing
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.09% to 40,452.70 while the NASDAQ rose 0.62% to 18,119.84. The S&P 500 also rose, gaining, 0.32% to 5,582.32. Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report Leading and Lagging SectorsConsumer discretionary shares jumped by 1% on Tuesday. In trading on Tuesday, energy shares fell by 1.4%. Top Headline GE Aerospace (NYSE:GE) reported better-than-expected second-quarter earnings and raised its FY24 outlook. GE Aerospace reported second-quarter 2024 adjusted revenue growth of 4% year-over-year to
U.S. stocks traded slightly higher this morning, with the Nasdaq Composite gaining around 0.2% on Tuesday. Following the market opening Tuesday, the Dow traded up 0.01% to 40,421.01 while the NASDAQ rose 0.19% to 18,041.10. The S&P 500 also rose, gaining, 0.18% to 5,574.56. Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report Leading and Lagging SectorsConsumer discretionary shares jumped by 0.8% on Tuesday. In trading on Tuesday, utilities shares fell by 0.5%. Top Headline General Motors Company (NYSE:GM) reported better-than-expected second-quarter earnings and raised its guidance. General Motors reported a fiscal second-quarter 202
- Reuters
Will Include Updates On Cancer Supportive Care Portfolio And Expansion Of Make Cancer Less Shitty Program With MCLS Ambassadors
Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositisCancer patients with diarrhea are 40% more likely to discontinue their therapy, and up to 40% of cancer patients experience the painful side effect of oral mucositisSAN FRANCISCO, CA / ACCESSWIRE / June 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it will hold an investor webcast on or before July 23, 2024 to provide results for the company's pivotal phase 3 OnTarget trial of crofelemer for prophylax